Groundbreaking Anti-Ageing Gene Therapy Enters Human Trials

Life Biosciences launches groundbreaking anti-ageing gene therapy in human trials, aiming to rejuvenate cells and treat optic nerve diseases

For the first time, a patient has received an experimental treatment designed to reverse cellular ageing, marking a significant step in regenerative medicine. The breakthrough anti-ageing gene therapy has entered human clinical trials after showing promising results in animal studies, sparking new optimism for treating age-related diseases.

Experimental Therapy Targets Ageing Cells

Developed by Boston-based biotechnology company Life Biosciences, the therapy known as ER-100 (AAV2-OSK) focuses on repairing damaged cells by using three proteins—Oct4, Sox2, and Klf4 (OSK). These proteins perform partial epigenetic reprogramming, a process intended to restore cells to a younger and healthier state without altering the underlying DNA sequence.

The company confirmed that the first participant has now received the anti-ageing gene therapy, making it the first epigenetic restoration treatment to reach human clinical testing.

Focus on Serious Eye Diseases

The Phase 1 trial is evaluating the therapy in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), two conditions that damage the optic nerve and can lead to permanent vision loss. Researchers hope rejuvenating affected cells could slow or even restore lost function.

Scientists believe ageing is driven partly by changes in the epigenetic code that controls gene activity. By resetting these changes, the treatment aims to reverse cellular decline rather than simply manage symptoms.

Inspired by Nobel Prize-Winning Research

The approach builds on discoveries that earned Sir John B. Gurdon and Shinya Yamanaka the 2012 Nobel Prize in Physiology or Medicine for demonstrating how mature cells can be reprogrammed into a more youthful state. Life Biosciences is applying similar principles in a targeted therapeutic setting.

Company co-founder David Sinclair described the trial as a landmark opportunity to test whether restoring epigenetic information can improve human disease.

Future Potential Beyond Vision Loss

While the study is primarily designed to assess safety, researchers believe the technology could eventually be expanded to treat liver disorders and other age-related conditions. Several biotechnology firms are also investing in similar approaches aimed at extending healthy lifespan and combating diseases linked to ageing.

The success of this anti-ageing gene therapy remains uncertain until clinical results become available, but the first human treatment represents a milestone in the growing field of longevity science.

FAQs

1. What is anti-ageing gene therapy?

Anti-ageing gene therapy is an experimental treatment that attempts to restore ageing cells to a younger state by modifying their epigenetic programming rather than changing DNA itself.

2. What is ER-100?

ER-100 is Life Biosciences’ investigational gene therapy that uses OSK proteins to partially reset damaged cells and potentially restore their function.

3. Which diseases are being studied in the trial?

The initial clinical trial focuses on open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), both of which affect the optic nerve.

4. Has this therapy been proven to reverse ageing in humans?

No. The first human has received the treatment, but the ongoing Phase 1 trial is primarily evaluating safety and effectiveness has not yet been established.

5. Why is this development important?

It is the first time a therapy specifically designed for epigenetic restoration and cellular rejuvenation has entered human clinical testing, potentially opening new avenues for treating age-related diseases.